The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40%...
Saved in:
Main Author: | Radcliffe NM |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/5aef8b2261c0435b9664d2c60ef48a3e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
by: Nicholas P Bell, et al.
Published: (2010) -
Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
by: Jaime Pablo Kelly Rigollet, et al.
Published: (2011) -
Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
by: Yoshikawa K, et al.
Published: (2014) -
Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
by: Jordão MLS, et al.
Published: (2014) -
Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
by: Norbert Pfeiffer, et al.
Published: (2010)